New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:08 EDTLLYEli Lilly's Cyramza for liver cancer did not meet Phase III primary endpoint
Eli Lilly announced that the Phase III REACH trial of Cyramza in patients with hepatocellular carcinoma or liver cancer, did not meet its primary endpoint; overall survival favored the Cyramza arm but was not statistically significant. There were meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression. The trial compared Cyramza plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with hepatocellular carcinoma after being treated with sorafenib in the first-line setting. No Phase III study of liver cancer has been able to demonstrate improved survival in the second-line setting. Lilly plans to present data from the REACH trial at a scientific meeting later this year.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
05:43 EDTLLYEli Lilly assumed with an Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Eli Lilly (LLY) to Overweight after assuming coverage of the name. Good execution for Cyramza and Jardiance should drive continued share outperformance, Meacham tells investors in a research note. He raised his price target for shares to $95 from $75. Lilly closed yesterday down $1.43 to $82.22. The analyst this morning also upgraded Johnson & Johnson (JNJ) and Merck (MRK) to Overweight and downgraded AbbVie (ABBV) to Equal Weight.
November 24, 2015
14:43 EDTLLYEli Lilly confirms FDA approval of Portrazza
Subscribe for More Information
11:48 EDTLLYFDA approves Portrazza to treat NSCLC
Subscribe for More Information
November 19, 2015
06:34 EDTLLYEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
November 18, 2015
08:11 EDTLLYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
06:09 EDTLLYValeant's Addyi sees hardly any sales, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use